Abstract
Epidemiological data have demonstrated a strong relationship between blood pressure (BP) and cardiovascular disease (CVD) risk and have shown the importance of systolic BP (SBP) as a determinant of such risk. The importance of BP as a risk factor has been further emphasized by a World Health Organization (WHO) report which identified high BP as one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. There is now data available on the safety and effectiveness of different classes of BP-lowering drugs, including diuretics, angiotensin-converting enzyme inhibitors (ACE-Is), dihydropyridine and non-dihydropyridine calcium channel blockers (CCBs), beta-blockers and angiotensin receptor blockers (ARBs). In this review we discuss classification of BP stages, goal of therapy, lifestyle modifications and optimal BP control in individual patients. The detection and optimal treatment of hypertension is likely to significantly ameliorate CVD risk.
Cardiovascular & Hematological Disorders-Drug Targets
Title: Contemporary Management of Hypertension - How to Optimize Therapy
Volume: 9 Issue: 3
Author(s): Steve Leung and Debabrata Mukherjee
Affiliation:
Abstract: Epidemiological data have demonstrated a strong relationship between blood pressure (BP) and cardiovascular disease (CVD) risk and have shown the importance of systolic BP (SBP) as a determinant of such risk. The importance of BP as a risk factor has been further emphasized by a World Health Organization (WHO) report which identified high BP as one of the most important preventable causes of premature morbidity and mortality in developed and developing countries. There is now data available on the safety and effectiveness of different classes of BP-lowering drugs, including diuretics, angiotensin-converting enzyme inhibitors (ACE-Is), dihydropyridine and non-dihydropyridine calcium channel blockers (CCBs), beta-blockers and angiotensin receptor blockers (ARBs). In this review we discuss classification of BP stages, goal of therapy, lifestyle modifications and optimal BP control in individual patients. The detection and optimal treatment of hypertension is likely to significantly ameliorate CVD risk.
Export Options
About this article
Cite this article as:
Leung Steve and Mukherjee Debabrata, Contemporary Management of Hypertension - How to Optimize Therapy, Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/187152909789007061
DOI https://dx.doi.org/10.2174/187152909789007061 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery Recent Patents on Polymeric Scaffolds for Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Inotropic Therapies in Asphyxiated Neonates: The Clinical and Laboratory Facts
Current Pediatric Reviews The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain Relief
Current Pharmaceutical Design Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Identification of Canonical Transient Receptor Potential (TRPC) Channel Proteins in Native Vascular Smooth Muscle Cells
Current Medicinal Chemistry Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews The Economics of Pharmacogenomics
Current Pharmacogenomics Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry Application of High Performance Liquid Chromatography for Hydrolytic Stability Assessment of Selected Antibiotics in Aqueous Environment
Current Analytical Chemistry Diet and Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemistry-based Design of Inhibitors for Carboxypeptidase A
Current Topics in Medicinal Chemistry Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Eye Disorders in Diabetes: Potential Drug Targets
Infectious Disorders - Drug Targets Biocatalysis: Synthesis of Chiral Intermediates for Pharmaceuticals
Current Organic Chemistry Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Lisinopril-loaded Chitosan Nanoparticles and Indapamide in Hard Gelatine Capsules: Simultaneous HPLC Quantification
Current Pharmaceutical Analysis